Skip to main content

Advertisement

SpringerLink
Log in

A Novel Method for Pain Relief in Chronic Pancreatitis: an Old Drug in a New Pack: a Controlled Study

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Most of pain-relieving agents in chronic pancreatitis are nonspecific and unpredictable. Omeprazole induces hypergastrinemia due to reduced gastric acidity. Raised serum gastrin, in turn, modulates to reduce secretin level. Secretin is responsible for secretion of almost 80 % bicarbonate-rich pancreatic juice from the ductular epithelium without affecting enzyme output. It is a prospective randomized study in patients with CT-confirmed chronic pancreatitis. The control group got the standard care and 60 mg of omeprazole twice daily was added to the test group. Absence of pain relief at 14 days was considered as failure. Pain relief, weight gain and any toxic effect of omeprazole were reviewed at 12 months. One hundred thirty-seven cases were included, with an age range of 19 to 72 years. (mean 42.67). The majority of them were alcoholic males. At 2 weeks, pain relief was noted in 47/69(68.1 %) and 63/65(96.96 %) in the control and omeprazole group, respectively. At the end of 1 year, the omeprazole group had greater weight gain (95 %) than the control group (69.5 %). All the pseudocysts in the omeprazole group and most in the control group resolved. No side effect of omeprazole was seen. The high-dose omeprazole (HDO) group of patients had significantly better pain relief in chronic pancreatitis than those treated with conventional therapy. A high number of cases gained weight in the HDO group than the controlled group. No patient had clinical, endoscopic, biochemical, or haematological toxicity of HDO. More studies are necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gachago C, Draganov PV (2008) Pain management in chronic pancreatitis. World J Gastroenterol 14:3137–3148

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lieb JG, Forsmark CE (2009) Review article: pain and chronic pancreatitis. Aliment Pharmacol Ther 29:706–719

    Article  CAS  PubMed  Google Scholar 

  3. Sand J, Lankisch PG, Nordback I (2007) Alcohol consumption in patients with acute or chronic pancreatitis. Pancreatology 7:147–156

    Article  CAS  PubMed  Google Scholar 

  4. Yadav D, Whitcomb DC (2010) The role of alcohol and smoking in pancreatitis. Nat Rev Gastroenterol Hepatol 7:131–145

    Article  PubMed  Google Scholar 

  5. Olesen SS, Bouwense SA, Wilder-Smith OH, van Goor H, Drewes AM (2011) Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Gastroenterology 141:536–543

    Article  CAS  PubMed  Google Scholar 

  6. Moreno Escobosa MC, Amat López J, Cruz Granados S, Moya Quesada MC (2005) Pancreatitis due to codeine. Allergol Immunopathol (Madr) 33:175–177

    Article  CAS  Google Scholar 

  7. Pandol SJ (2010) Pancreatic secretion. In: Feldman M, Friedman LS, Brandt LJ (eds) Sleisenger and Fordtran’s gastrointestinal and liver disease, 9th edn. Saunders Elsevier, Philadelphia, pp. 921–930

    Chapter  Google Scholar 

  8. You CH, Chey WY (1987) Secretin is an enterogastrone in humans. Dig Dis Sci 32:466–471

    Article  CAS  PubMed  Google Scholar 

  9. Konturek SJ, Pucher A, Radecki T (1976) Comparison of vasoactive intestinal peptide and secretin in stimulation of pancreatic secretion. J Physiol 255:497–509

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lambrecht N, Corbett Z, Bayle D, Karlish JDS, Sachs G (1998) Identification of the site of inhibition by omeprazole of a α-β fusion protein of the H+ K+ ATPase using site directed mutagenesis. J Biol Chem 273:13719–13728

    Article  CAS  PubMed  Google Scholar 

  11. Rost KL, Roots I (1996) Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 23:1491–1497

    Article  CAS  PubMed  Google Scholar 

  12. Joelson S, Joelson IB, Lundborg P, Walan A, Wallander MA (1992) Safety experience from long-term treatment with omeprazole. Digestion 51:93–101

    Article  PubMed  Google Scholar 

  13. Poulsen JL, Olesen SS, Malver LP, Frøkjær JB, Drewes AM (2013) Pain and chronic pancreatitis: a complex interplay of multiple mechanisms. World J Gastroenterol 19(42):7282–7291. doi:10.3748/wjg.v19.i42.7282.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kiley CA, Cragin DJ, Roth BJ (2007) Omeprazole-associated digoxin toxicity. South Med J 100:400–402 Comment in South Med J. 2007;100:345-6

    Article  PubMed  Google Scholar 

  15. Mignon M, Pospai D, Forestier S, Vatier J, Vallot T (1993) Treatment of patients with Zollinger-Ellison syndrome. Clin Ther 15(Suppl B):22–31

    PubMed  Google Scholar 

  16. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, Gardner JD, Jensen RT (1989) Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology 97:827–836

    Article  CAS  PubMed  Google Scholar 

  17. Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C (1985) Toxicological studies on omeprazole. Scand J Gastroenterol Suppl 108:53–69

    CAS  PubMed  Google Scholar 

  18. Kohler JE, Blass AL, Liu J, Tai K, Soybel DI (2010) Antioxidant pre-treatment prevents omeprazole-induced toxicity in an in vitro model of infectious gastritis. Free Radic Biol Med 49:786–791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB (2003) Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol 9:2565–2569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Vecht J, Symersky T, Lamers CB, Masclee AA (2006) Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. J Clin Gastroenterol 40:721–725

    Article  CAS  PubMed  Google Scholar 

  21. Sablin OA, Ratnikov VA, Butenko EV, Pakhomova IG (2002) Clinical aspects of using pariet in treating chronic pancreatitis. Eksp Klin Gastroenterol 129(5):73–76

    Google Scholar 

  22. Puylaert M, Kapural L, Van Zundert J, Peek D, Lataster A, Mekhail N, van Kleef M, Keulemans YC (2011) Pain in chronic pancreatitis. Pain Pract 11:492–505

    Article  PubMed  Google Scholar 

  23. Kemmer TP, Malfertheiner P, Büchler M, Friess H, Meschenmoser L, Ditschuneit H (1992) Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995). Aliment Pharmacol Ther 6:41–50

    Article  CAS  PubMed  Google Scholar 

  24. Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, Büchler MW (1994) Inhibition of pancreatic secretion under long-term octreotide treatment in humans. Digestion 55(Suppl 1):10–15

    Article  CAS  PubMed  Google Scholar 

  25. Lieb JG 2nd, Shuster JJ, Theriaque D, Curington C, Cintrón M, Toskes PP (2009) A pilot study of octreotide LAR vs. octreotide tid for pain and quality of life in chronic pancreatitis. JOP 10:518–522

    PubMed  Google Scholar 

  26. Harris AG (1994) Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut 35(3 Suppl):S1–S4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Saif MW, Larson H, Kaley K, Shaib W (2010) Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saf 9:867–873

    Article  CAS  PubMed  Google Scholar 

  28. Gyr KE, Meier R (1993) Pharmacodynamic effects of sandostatin in the gastrointestinal tract. Digestion 54(Suppl 1):14–19

    Article  CAS  PubMed  Google Scholar 

  29. Kapuscinski M, Shulkes A (1995) Secretory and biosynthetic responses of gastrin and somatostatin to acute changes in gastric acidity. J Gastroenterol Hepatol 10:405–412

    Article  CAS  PubMed  Google Scholar 

  30. Chey WY, Chang TM (2014) Secretin: historical perspective and current status. Pancreas 43:162–182

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

My sincere thanks to Drs Group Captain Rajesh Gangavatiker (Surgical gastroenterologist, (IAF) and Colonel TS Ramakrishnan for their kind support on study design ansd stastical work during the study).

Author information

Authors and Affiliations

  1. Department of Surgery, Vydehi Medical College, Bangalore, Karnataka, PIN 560066, India

    Aswini Kumar Pujahari

Authors
  1. Aswini Kumar Pujahari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aswini Kumar Pujahari.

Ethics declarations

Conflict of Interest

The author declares that there is no conflict of interest.

Electronic supplementary material

ESM 1

(DOC 40 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pujahari, A.K. A Novel Method for Pain Relief in Chronic Pancreatitis: an Old Drug in a New Pack: a Controlled Study. Indian J Surg 79, 549–554 (2017). https://doi.org/10.1007/s12262-016-1526-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-016-1526-6

Keywords

Search

Navigation